Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
Covered in this story
What has happened since
- Biogen is up 4.4% since this was published, 24 days ago.
- AbbVie is up 5.1% since this was published, 24 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
Wolfe Research’s $300 target on $BIIB is on the record and being tracked to Sep 2027 (12-month default), scored on the close that day.
Wolfe Research’s track record →Tracked from this story
Wolfe Research’s $300 target on $ABBV is on the record and being tracked to Sep 2027 (12-month default), scored on the close that day.
Wolfe Research’s track record →Analyst targets on Biogen
- H.C. Wainwright: $203 → $251 by Jul 2027 · Buy via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $BIIB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Biogen →Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.